June 2025

As NETRF celebrates 20 years of advancing neuroendocrine cancer research, we're launching our boldest initiative: a $25 million campaign to accelerate life-changing diagnostics, treatments, and precision medicine by 2030. To see the impact NETRF has had in its first 20 years, browse the timeline in the 2024 annual report. 

"Breakthroughs Today, Cures Tomorrow" showcases powerful voices from our community—researchers, patients, families, and board members who are driving change. Each story reveals why NETRF's work is essential and how every breakthrough brings us closer to cures.

Your impact doubles right now. Through June 30th, Board Member Steve Kaufer is matching every donation dollar-for-dollar up to $100,000.

The future of neuroendocrine cancer research depends on what we do today.

Explore the campaign and make your matched gift. 

More positive news about the CAR T-cell clinical trial! CAR T-cell therapy for GEP-NETs, now in clinical trial, has been granted Fast Track Designation by the US Food and Drug Administration. NETRF funded the preclinical development of CHM CDH17 by Dr. Xianxin Hua at the University of Pennsylvania. Chimeric Therapeutics, an Australian company, developed the clinical trial. Read how this designation could speed up the development and review of this potential new treatment. 

Neuroendocrine cancer research continues to evolve, with a growing number of clinical trials exploring bold, highly targeted strategies aimed at treating advanced and high-grade disease. From radiopharmaceuticals and drug conjugates to viral therapies and T-cell engagers, these studies reflect the evolving science behind how we detect, target, and treat neuroendocrine cancer. Learn more.

A study published this month by NETRF-funded Collaborative Grant recipient Sharon Gorski, PhD, in Scientific Reports offers fresh insight into the complex biology of metastatic neuroendocrine neoplasms (NENs). This study of NET and NEC samples highlights the power of precision medicine for improving outcomes in neuroendocrine cancer. Read more.

New research, including a comprehensive review just published in Endocrine-Related Cancer by NETRF-funded researchers Aatur Singhi, MD, PhD, Christopher Heaphy, PhD, and others, challenges the assumption that small non-functional PanNETs are low-risk and underscores the need for a more nuanced approach to managing these tumors. Read more.

At NETRF, our annual Request for Applications (RFA) is a cornerstone of our mission to fund innovative research in neuroendocrine cancer. This two-stage process is designed to identify and support the most promising, high-impact projects. Learn more. 

In this episode of NETWise, we continue our focus on neuroendocrine carcinoma, a rare and aggressive form of neuroendocrine cancer. While our previous episode explored diagnosis and treatment, this discussion centers on the unique challenges faced by caregivers. Caring for someone with neuroendocrine carcinoma can be incredibly intense due to the cancer’s rapid progression and limited effective treatment options. This episode highlights the emotional and physical toll of caregiving—and emphasizes the vital importance of self-care for those supporting a loved one through this difficult journey.

This Thrivership Series session, “Living with Uncertainty,” explores the psychology of uncertainty and how this applies to a neuroendocrine cancer journey. Watch the session to learn practical tools and emotional strategies to help navigate the unknown with resilience and clarity.

We are deeply grateful to designer denim brand Citizens of Humanity, Simone Harouche, and Jared Freedman for honoring the memory of Lindsay May Palevsky with the launch of The Lindz jean—an inspiring tribute to a beloved friend and a powerful step forward in raising awareness of neuroendocrine cancer.

Named for Lindsay, who died of neuroendocrine cancer in November 2024, The Lindz launch reflects her vibrant spirit 

and enduring impact. In addition to bringing attention to this often-misdiagnosed disease, the initiative will also support critical research: $50 from every online sale of The Lindz will be donated to NETRF through the end of 2025.

The launch was marked by a moving Instagram video tribute—shared jointly by Citizens of Humanity and NETRF—that has reached more than 2 million viewers in its first 24 hours. Celebrities including Kim Kardashian and Nicole Richie joined in amplifying Lindsay’s story via social media, some tagging and mentioning NETRF in their content. 

The Lindz is available for purchase on the Citizens of Humanity website, and you can watch the video tribute to Lindsay on Instagram. 

Monte Roach and friends gathered for the Joel Frank Memorial Golf Tournament.

Matt Mueller and NETRF Board Member Suzanne Ludlow at the Katherine's Light Foundation Music Festival.

We’re so grateful to the generous friends of NETRF who hosted incredible fundraisers this June in support of neuroendocrine cancer research. Special thanks to Monte Roach and friends of Joel Frank for the 2025 Joel Frank Memorial Golf Tournament in Cedarburg, WI, which has raised over $10,000 and counting; to Katherine’s Light Foundation for their all-day event in Severna Park, MD, bringing their all-time fundraising total to over $200,000; to the Queenan family for honoring Carolyn Queenan with a golf tournament in Hyannis, MA, and to Jim Gray for posting an online fundraiser on Facebook, as a tribute to his late son, Justin. So far, Jim has raised over $6,000.

Your dedication fuels progress and brings hope.

Interested in hosting a community fundraiser? Contact Steve Perna at steve.perna@netrf.org.

The neuroendocrine cancer community has lost one of its pioneers. Dr. Richard Warner died on June 15 at the age of 97. Dr. Warner helped define and develop the field of neuroendocrine cancer. In 1968, he established the Carcinoid Cancer Foundation. In 2006, he was a founding member of the North American Neuroendocrine Society (NANETS). In 2007, Dr. Warner was appointed Professor of Medicine in gastroenterology at The Icahn School of Medicine at Mount Sinai in New York. He established the Center for Carcinoid and Related Neuroendocrine Tumors and the Serotonin Research Laboratory at Mount Sinai.

Dr. Warner touched the lives of so many patients and generously shared his knowledge with NET specialists. The NETRF team sends our sympathies to Dr. Warner’s family.

NET Research Foundation
100 Hancock Street,
Third floor
Quincy, MA 02171
(617) 946-1780 info@netrf.org

The mission of the Neuroendocrine Tumor Research Foundation is to fund research to discover cures and more effective treatments for neuroendocrine cancer. NETRF is the largest global funder of neuroendocrine research and a preeminent resource for expert patient education and support.



NETRF is a 501(c)(3) organization. All donations are tax-deductible to the extent allowed by law.